Thursday - June 11, 2026

Category Archives: Science

Chronic Kidney Disease Drug Development Pipeline Expands as 75+ Companies Focus on Novel Mechanisms of Action | DelveInsight

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Multiple System Atrophy Clinical Pipeline Intensifies with 20+ Industry Players Exploring Breakthrough Treatment Modalities | DelveInsight

DelveInsight’s “Multiple System Atrophy Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Triple Negative Breast Cancer Clinical Trial Landscape Advances Rapidly as 165+ Companies Innovate in Targeted Biologic Therapies | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and … Continue reading →

Rheumatoid Arthritis Pipeline Shows Strong Momentum as 75+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Rheumatoid Arthritis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Rheumatoid Arthritis (RA) pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading →

Psoriasis Pipeline Expands as 65+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Psoriasis Pipeline Insight, 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline … Continue reading →

Myelofibrosis Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Myelofibrosis Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment … Continue reading →

Hidradenitis Suppurativa Pipeline Gains Momentum: 24+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Hidradenitis Suppurativa Pipeline Insight 2026” report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in Hidradenitis Suppurativa pipeline landscape. It covers the Hidradenitis Suppurativa Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Obstructive Sleep Apnea Pipeline Shows Potential with Active Contributions from 18+ Key Companies | DelveInsight

DelveInsight’s “Obstructive Sleep Apnea Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Chronic Myeloid Leukemia Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

The market dynamics for Chronic Myeloid Leukemia (CML) are witnessing substantial growth driven by the increasing incidence of CML, growing adoption of targeted therapies, rising awareness regarding molecular diagnostics, and advancements in tyrosine kinase inhibitor (TKI) therapies. Additionally, the launch … Continue reading →

Sjogren’s Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Emerging Disease-Modifying Therapies | DelveInsight

The market dynamics for Sjogren’s Syndrome are witnessing steady growth driven by the increasing prevalence of autoimmune disorders, rising awareness regarding early diagnosis, growing burden of chronic dry eye and dry mouth conditions, and increasing demand for effective disease-modifying therapies. … Continue reading →